Agilon Health (NYSE: AGL) surged more than 105% in May after reporting Q1 2026 EPS of $1.80, more than double the $0.83 consensus estimate, on adjusted EBITDA of $53.84 million that beat expectations by 48.9%. The company raised full-year 2026 revenue guidance to $5.74 billion an